Aytu BioPharma (NASDAQ:AYTU) Stock Price Passes Below 50-Day Moving Average of $0.57

Aytu BioPharma, Inc. (NASDAQ:AYTUGet Rating)’s stock price crossed below its fifty day moving average during trading on Friday . The stock has a fifty day moving average of $0.57 and traded as low as $0.52. Aytu BioPharma shares last traded at $0.56, with a volume of 321,899 shares trading hands.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on AYTU shares. Cantor Fitzgerald cut their target price on shares of Aytu BioPharma from $11.00 to $5.00 in a report on Tuesday, May 17th. HC Wainwright cut their price target on shares of Aytu BioPharma from $11.00 to $6.00 and set a “buy” rating for the company in a report on Thursday, July 21st.

Aytu BioPharma Price Performance

The company has a debt-to-equity ratio of 0.30, a current ratio of 0.97 and a quick ratio of 0.80. The stock’s fifty day moving average is $0.57 and its 200-day moving average is $0.84. The stock has a market cap of $21.60 million, a PE ratio of -0.14 and a beta of -0.42.

Aytu BioPharma (NASDAQ:AYTUGet Rating) last announced its quarterly earnings data on Monday, May 16th. The company reported ($0.27) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.41) by $0.14. Aytu BioPharma had a negative net margin of 120.24% and a negative return on equity of 41.97%. The firm had revenue of $24.20 million during the quarter, compared to analyst estimates of $24.20 million. As a group, equities analysts anticipate that Aytu BioPharma, Inc. will post -1.05 EPS for the current year.

Institutional Investors Weigh In On Aytu BioPharma

An institutional investor recently raised its position in Aytu BioPharma stock. Renaissance Technologies LLC lifted its position in Aytu BioPharma, Inc. (NASDAQ:AYTUGet Rating) by 15.1% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 765,469 shares of the company’s stock after purchasing an additional 100,400 shares during the quarter. Renaissance Technologies LLC owned about 2.29% of Aytu BioPharma worth $827,000 at the end of the most recent reporting period. 11.47% of the stock is currently owned by institutional investors and hedge funds.

Aytu BioPharma Company Profile

(Get Rating)

Aytu Biopharma, Inc, a specialty pharmaceutical company, focuses on developing and commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company offers Adzenys XR-ODT for the treatment of attention deficit hyperactivity disorder (ADHD) in patients from 6 years and older; Cotempla XR-ODT for the treatment of ADHD in patients from 6 to 17 years old; and Adzenys ER, an oral suspension for the treatment of ADHD in patients from 6 years and older.

Featured Stories

Receive News & Ratings for Aytu BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aytu BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.